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This editorial refers to ‘Network meta-analysis:
simultaneous meta-analysis of common antiplatelet
regimens after transient ischaemic attack or stroke’† by
V. Thijs et al., on page 1086
Network meta-analysis is a fairly new method for assessing the
relative effectiveness of two treatments when they have not
been directly evaluated in a controlled randomized trial (CRT)
but have each been compared with other treatments.1 It allows
an estimation of the heterogeneous effect of any given treatment
and for inconsistency in the evidence from different pairs of treat-
ments.1 It has also been used to compare the efficacy of different
therapies, such as the effect of antihypertensive drugs on health
care outcomes2 and on the incidence of diabetes mellitus,3 of
antithrombotic treatment on stroke prevention in non-rheumatic
atrial fibrillation,4 and of drug-eluting and bare-metal stents on
outcome.5
The efficacy of antiplatelet agents in secondary stroke preven-
tion has been investigated in CRTs comparing one antiplatelet
agent with another and with a placebo, and a combination of
two antiplatelet agents with a placebo and with another antiplate-
let drug. Aspirin,6 ticlopidine,7 and dipyridamole and aspirin plus
dipyridamole8 have been shown to be more effective than
placebo alone. In contrast, a comparison of ticlopidine with
aspirin produced contradictory results.9– 11 A post hoc subgroup
analysis of the Clopidogrel versus Aspirin in Patients at Risk of
Ischaemic Events (CAPRIE) study showed no advantage of clopido-
grel compared with aspirin alone in secondary stroke prevention.12
However, CAPRIE was not set up for detecting significant differ-
ences in this subgroup.12 The combination of aspirin and clopido-
grel was not more effective than either aspirin alone13 or
clopidogrel alone.14 In contrast, the European Stroke Prevention
Study 2 (ESPS)8 and a meta-analysis15 have reported that aspirin
plus dipyridamole is more effective than placebo, aspirin, or dipyr-
idamole. The aspirin dose used in ESPS 2 (50 mg/day),8 and in
50% of the patients of the European/Australasian Stroke Preven-
tion in Reversible Ischaemia Trial (ESPRIT; 30–50 mg/day),15 was
,75 mg/day, which was not more effective than placebo in the
meta-analysis of the Antithrombotic Trialists’ Collaboration.6
These findings indicate that further studies and/or analyses,
which compare the aforementioned antithrombotic treatments,
in particular aspirin plus dipyridamole with aspirin 75 mg/day
and clopidogrel, are needed. Thijs et al.16 have addressed most
of these questions using network meta-analysis. The authors com-
pared the efficacy of antiplatelet agents and combinations of such
agents (aspirin, aspirin plus dipyridamole, the thienopyridines ticlo-
pidine and clopidogrel, and the combination of aspirin and thieno-
pyridines) in the prevention of serious vascular events after stroke
and transient ischaemic attacks (TIAs). As expected, all antiplatelet
regimens were more effective than placebo, and aspirin plus dipyr-
idamole was more effective than aspirin alone.16 Interestingly, the
combination of aspirin with dipyridamole was also more effective
than the thienopyridines (odds ratio, 0.84; 95% confidence interval,
0.73–0.97).16
Network meta-analysis has been criticized, because it may
combine evidence from trials that are substantially different in
design.17 Another limitation is the reliance on random effect
methods for meta-analyses, which allow smaller studies a greater
effect. Thereby, a small outlying trial can have undue influence.
The Prevention Regimen for Effectively Avoiding Second Strokes
(PRoFESS) trial uses a 2  2 factorial design to compare the effi-
cacy of aspirin plus dipyridamole with clopidogrel, and telmisartan
with placebo for secondary stroke prevention in .20 000 patients
with ischaemic stroke.18 The ProFESS trial will allow the validity of
the network meta-analysis of Thijs et al.16 to be evaluated.
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